在55岁及以上的多发性硬化症患者中,实践中使用疾病修饰疗法
Mina Stanikić1,2, Anke Salmen3, Christian P Kamm4,5
1Department of Epidemiology, University of Zurich Institute of Epidemiology Biostatistics and Prevention, Zürich, Switzerland.
BMJ neurology open
|September 26, 2025
概括
患有多发性硬化症 (MS) 的老年人继续接受疾病修饰疗法 (DMT),尽管指导方针不清楚. 复发性复发性多发性硬化与DMT使用有关,而年龄和疾病持续时间显示的关联很小.
科学领域:
- 神经学 神经学
- 临床实践 临床实践
- 流行病学 流行病学
背景情况:
- 多发性硬化症 (MS) 人口的平均年龄在全球上升.
- 在老年患有多发性硬化症 (pwMS) 患者中使用疾病修饰疗法 (DMT) 的指导方针不清楚.
- 需要了解在这个人口群体中影响DMT使用的因素.
研究的目的:
- 探索55岁及以上的pwMS中DMT使用模式.
- 为了确定与使用DMT与不使用DMT相关的因素,在老年PWMS中.
- 分析DMT延续,切换和开始在老龄化多发性硬化群体中的情况.
主要方法:
- 从瑞士MS注册表 (SMSR) 的数据进行探索性分析.
- 根据目前和过去的DMT使用情况对参与者的分类 (没有DMT,停止,继续,切换者,新).
- 逻辑双项回归用于识别与DMT不使用相关的因素.
主要成果:
- 在378名参与者中,54.5% (平均年龄63.2岁) 报告使用DMT.
- 在那些定期接受神经治疗的人群中,不使用DMT的可能性更高,与MS持续时间更长和年龄更大有关.
- 初级和二级渐进性MS与不使用DMT相比,与复发性复发性MS相比,与不使用DMT更为相关.
结论:
- 许多年长的pwMS继续使用DMT,尽管有效性和安全性不确定.
- 在老年PWMS中使用DMT主要与复发性复发性MS有关.
- 年龄和疾病持续时间在这个人群中与DMT使用的相关性有限.
相关概念视频
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188
01:22Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
01:24Parkinson's Disease: Treatment
986
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
986
01:15Drug Dosing: Geriatric Patients
227
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
227
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
01:20Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K